Quantum-Si Incorporated

Good day and thank you for standing by. Welcome to the Quantum SI second quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I'd now like to turn the conference over to Risa Lindsay.

Good afternoon, everyone, and thank you for joining us. Earlier today, Quantum SI released financial results for the second quarter and six months ended June 30th, 2026. A copy of the press release is available on the company's website. Joining me today are Jeff Hawkins, our president and chief executive officer, as well as Jeff Keyes, our chief financial officer. Before we begin, I would like to remind you that management will be making certain forward-looking statements within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements of our press release. For a more complete list and description of risk factors, please see the company's filings made with the Securities and Exchange Commission. This conference call contains time-sensitive information that is accurate only as of the live broadcast date, today, August 13, 2026, at 1.30 p.m. Pacific Time. Except as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements. During this call, we will also be referring to certain financial measures that are not prepared in accordance with U.S. generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the press release filed earlier today. With that, let me turn the call over to Jeff Hawkins.

Good afternoon and thank you for joining us. On today's call, we will provide a business update and review our operating results for the second quarter of 2026. After that, we will open the call for questions. Before diving into specific updates, I want to address at a high level the Proteus roadmap update we announced earlier today. We have updated the Proteus launch timeline from the end of 2026 to the second quarter of 2027. The primary driver of the change is the decision to add an additional integrated instrument design cycle to the program prior to moving to production. In connection with this roadmap review, we have also made program leadership and governance changes to strengthen accountability, improve technical oversight, and ensure the Proteus program is managed against clear product readiness gates. Furthermore, we are taking operating expense actions in parallel with this roadmap update that are designed to reduce our cash burn and align our cost structure with the revised timeline while preserving investments in the highest priority Proteus workstreams. Our conviction in Proteus remains strong. We have generated sufficient sequencing data from integrated units that we remain confident in the underlying technology. That said, we are taking these actions now because we believe it is more responsible and capital efficient to de-risk the platform before production than to move forward Thank you all for joining us. Our first priority is to deliver Proteus with the capabilities customers need. First, let's start by diving a bit deeper into the instrument development. In 2025, we built and tested Proteus prototypes. In the first half of 2026, we built and began testing integrated units. Those integrated units have generated valuable learnings about both manufacturing processes and system level performance that prototypes could not fully provide. Based on that testing, we concluded that moving directly from the current integrated unit design to production would carry more execution risk than we are comfortable with taking. We are therefore adding an additional integrated instrument design cycle before moving into production. The purpose of this additional design cycle is to reduce manufacturing risk, improve system repeatability, strengthen product readiness, and to ensure a positive customer experience at launch. We are making this decision now because we believe it is more responsible and more capital efficient to de-risk the platform before production than to scale prematurely and put the customer experience at risk. Finally, I want to reiterate that we have generated sufficient sequencing data from integrated units that we remain confident in the underlying technology. Turning now to recognizer development, we communicated on our first quarter earnings call that our internal developmental sequencing kit was able to detect 17 amino acids. Our progress in this area and the pace of improvement we are seeing has continued to meet our expectations. Given the revised instrument timeline, we will be able to progress even further in this area before locking the reagent formulation for launch. We believe that with this additional time, we will be in a strong position to deliver Proteus with a detection capability of either 19 or 20 amino acids at launch. We will have greater clarity on the specific reagent configuration when we get closer to launch. Finally, I want to share an important update on our library preparation strategy. As a reminder, library preparation is the process used to prepare a customer sample for sequencing. Our kit performs two key functions, digesting proteins into peptides and attaching a linker to those peptides. That linker enables each peptide to attach to the bottom of the nanowells on our sequencing array where it can be sequenced as a single molecule. Historically, we approach library preparation as a general purpose kit intended to work across the broad range of proteins and applications. One of the important benefits of having our first generation platinum system in the market is that we have gained significant real world insight into how different proteins behave during library preparation, as well as customer needs across the range of applications. Through our work supporting Platinum customers, we have also developed improvements and add on capabilities related to library preparation, both internally and in some cases in collaboration with customers. These learnings have led us to an important strategic shift, evolving from a single generic kit to a suite of application oriented kits that can be used individually or in combination to optimize sequencing performance for specific customer use cases. We believe this strategy provides two key advantages. First, by giving customers more complete off the shelf tools tailored to their applications, we can make implementation more efficient and reduce the amount of customer optimization required. Second, this approach allows our development teams to deliver a broad range of capabilities faster and with lower technical risks. developing kits around more specific application needs is less complex than trying to make one generic kit which performs optimally across every protein type and workflow. We are excited about this strategy and believe it positions us to bring new library preparation capabilities to market in connection with the Proteus launch. Our second corporate priority is to prepare the market for Proteus launch. As a reminder, during 2025, we launched a placement program for our first generation platinum system. This program allows customers to access the platinum instrument in their own labs without needing to secure budget for an upfront capital purchase. Through this program, we have gained important market and technical insights that give us increasing confidence in the opportunity for protein sequencing and in the alignment between customer requirements and our target specifications for Proteus. First, we have had the opportunity to work with customers across a broad range of applications spanning academic research and biopharma. One recent example is work we have been doing with a biopharma customer in Europe on the application of protein sequencing to adeno-associated viral vectors or AAV serotyping. AAVs are commonly used as delivery vehicles in gene therapy, and the presence and relative abundance of different AAV serotypes is important to therapy performance. This application is well suited to protein sequencing because the differences between AAV serotypes often involves only a small number of amino acid differences. With platinum, we have been able to demonstrate the ability to detect relevant amino acid differences. However, due to the limited sequencing output of platinum, we did not reach the sensitivity required for routine use in that customer workflow. Importantly, Using the platinum data, we were able to model expected performance on Proteus based on its planned increase in number of nanowells, and that model suggests the customer sensitivity requirement is achievable on Proteus. Based on readily available market data, there are more than 150 biotech and pharmaceutical companies developing gene therapies that use AAVs for delivery, suggesting that this single application could represent an attractive market opportunity for Proteus. A second important learning from our platinum commercial activities is the potential opportunity in non-human proteomics. Earlier this year, researchers at the U.S. Naval Research Laboratory published data using our single molecule protein sequencing technology for novel pathogen and toxin detection. Over the past few months, we have been working with multiple customers applying protein sequencing to agricultural applications, pathogen detection and typing, and viral protein surveillance applications. We have identified two important features of non-human proteomics that make it especially interesting for Proteus. First, many of these markets are not well served by traditional techniques such as immunoassays or Western blots. Second, in many applications, customers need a technology that does not depend on a defined reference because the pathogen or protein of interest may evolve through small changes including single amino acid differences. These market features align well with the core capabilities we are designing into Proteus. Based on readily available market data and looking specifically at the pathogen research and agricultural research markets where our platinum work has given us a clear understanding of customer needs, we believe the non-human proteomics market opportunity for Proteus is substantial at more than $4 billion annually. We believe this is a conservative estimate because it does not include additional segments such as environmental, animal health, industrial, or food applications where we believe there may be meaningful future opportunity, but where our understanding of the specific customer needs and fit for protein sequencing is still developing. Finally, I want to provide a brief update on our commercial initiatives to build awareness of Proteus in advance of launch. Our commercial team has been executing well and we continue to receive very positive feedback on Proteus and the wide range of applications it is designed to address. To date, we have identified and qualified more than 250 unique institutions with stated interest in Proteus and the capabilities we are aiming to deliver. These institutions span multiple market segments, including academic research, biopharma, and industrial applications, and they have asked to be updated as new information and data become available. We will continue to provide updates on this important market develop initiative as we progress toward the Proteus launch. Our third priority is to preserve our financial strength. As I stated earlier, the operating expense actions we communicated today are intended to reduce cash burn, extend our runway, and align our cost structure with the revised Proteus timeline while preserving investments in the highest priority work streams required for launch. We are making these decisions as a matter of fiscal discipline, Our focus is to concentrate resources on the activities that most directly improve Proteus readiness, de-risk the platform before production, and allow us to fund that work responsibly over the extended timeline. I will now turn the call over to Jeff to review our financial results.